ir para o conteúdo principal
Logo Default

IPO Coimbra

IPO Coimbra

Institution Description

The Portuguese Institute of Oncology of Coimbra Francisco Gentil, EPE (IPO of Coimbra) is today a reference institution in the provision of health care to cancer patients. With full accreditation since 2005 by Caspe Healthcare Knowledge Systems (CHKS) and since 2011 by the Organization of European Cancer Institutes (OECI) as Clinical Cancer Center, the Coimbra IPO has been strengthening its role in the healthcare network in the Center Region, in the community of patients and families it serves and among other partners, in a logic of proximity and humanization.

Having multidisciplinarity as a fundamental premise in Oncology, it develops its activity in Multidisciplinary Pathology Groups, focused on caring for the patient during the course of the disease and in all its dimensions. In this perspective, it is organized around the expectations and needs of patients and families, committing to carry out the best clinical practices with regard to access, quality and safety, productivity and economic and financial performance, in a culture of responsibility, sustainability and social cohesion.

Research is a strategic pillar of Clinical and Institutional Governance in the 2021-2023 triennium. Responding to the challenges of knowledge in Oncology implies assuming a strategic vision for research, development and innovation, fostering the convergence of areas of knowledge, streamlining access to support structures for research projects, maximizing human capital with the integration of multidisciplinary projects , in cooperation with other national and international research units or centers, leveraging scientific evidence that supports the provision of better health care to cancer patients.

With the recent restructuring of the Research Coordinating Office, the IPO of Coimbra bets on differentiated professionals who are capable of developing clinical, basic and transactional research, having created the Fund for Research, which will allow the financing of research through the attribution of prizes and grants . Thus, it assumes clinical trials as essential for an excellent clinical practice in Oncology.

Year

Download
General Indicators
No. of active clinical studies by study type
  • 20
    Active Clinical Trials
  • 16
    Active Non-Interventional Studies
No. of initiated clinical studies by study type
  • 5
    Clinical Trials initiated
  • 9
    Non-Interventional Studies initiated
No. of active non-interventional clinical studies by therapeutic area
No. of active non-interventional clinical studies by sponsor type
No. of active Clinical trials by sponsor type
No. of active clinical trials per phase
No. of active clinical trials by trial object
No. of active clinical trials by therapeutic area
  • 150
    No. of publications in indexed journals - last 5 full years
  • 95
    No. of health professionals with specific training in GCP (Good Clinical Practices)
Global Capacity Indicators
  • 134
    No. of available beds in the institution
  • 200
    No. of Physicians in the Institution
  • 281
    No. of Nurses in the Institution
  • 10
    No. of Pharmacists in the Institution
  • 2,5 millions
    No. of Inhabitants covered by the institution
HR Indicators Allocated to Research
Total number of people dedicated to clinical research in the institution
  • 40
    Researchers
  • 6
    Managers, Administrative, Legal and Financial
  • 2
    Study coordinators
  • 14
    Nurses
  • 10
    Pharmacists
Efficiency Indicators
  • 42
    Total number of participants recruited for clinical trials and interventional clinical studies of medical devices
  • 85%
    Patient recruitment rate in clinical trials and interventional clinical studies of medical devices
  • 30 days
    Average time to first patient recruitment in clinical trials and interventional clinical studies of medical devices
  • 15 days
    Average time between submission and approval of the Financial Contract in clinical trials and interventional clinical studies of medical devices
General Indicators
No. of active clinical studies by study type
  • 15
    Active Clinical Trials
  • 8
    Active Non-Interventional Studies
No. of initiated clinical studies by study type
  • 5
    Clinical Trials initiated
  • 4
    Non-Interventional Studies initiated
No. of active non-interventional clinical studies by therapeutic area
No. of active non-interventional clinical studies by sponsor type
No. of active Clinical trials by sponsor type
No. of active clinical trials per phase
No. of active clinical trials by trial object
No. of active clinical trials by therapeutic area
  • 126
    No. of publications in indexed journals - last 5 full years
  • 84
    No. of health professionals with specific training in GCP (Good Clinical Practices)
Global Capacity Indicators
  • 219
    No. of available beds in the institution
  • 199
    No. of Physicians in the Institution
  • 287
    No. of Nurses in the Institution
  • 8
    No. of Pharmacists in the Institution
  • 2.500 millions
    No. of Inhabitants covered by the institution
HR Indicators Allocated to Research
Total number of people dedicated to clinical research in the institution
  • 40
    Researchers
  • 6
    Managers, Administrative, Legal and Financial
  • 2
    Study coordinators
  • 14
    Nurses
  • 8
    Pharmacists
Efficiency Indicators
  • 30
    Total number of participants recruited for clinical trials and interventional clinical studies of medical devices
  • 85%
    Patient recruitment rate in clinical trials and interventional clinical studies of medical devices
  • 30 days
    Average time to first patient recruitment in clinical trials and interventional clinical studies of medical devices
  • 15 days
    Average time between submission and approval of the Financial Contract in clinical trials and interventional clinical studies of medical devices
General Indicators
No. of active clinical studies by study type
  • 22
    Active Clinical Trials
  • 6
    Active Non-Interventional Studies
No. of initiated clinical studies by study type
  • 6
    Clinical Trials initiated
  • 0
    Non-Interventional Studies initiated
No. of active non-interventional clinical studies by therapeutic area
No. of active non-interventional clinical studies by sponsor type
No. of active Clinical trials by sponsor type
No. of active clinical trials per phase
No. of active clinical trials by trial object
No. of active clinical trials by therapeutic area
  • 50
    No. of publications in indexed journals - last 5 full years
  • 95
    No. of health professionals with specific training in GCP (Good Clinical Practices)
Global Capacity Indicators
  • 177
    No. of available beds in the institution
  • 212
    No. of Physicians in the Institution
  • 293
    No. of Nurses in the Institution
  • 10
    No. of Pharmacists in the Institution
  • 2,5 millions
    No. of Inhabitants covered by the institution
HR Indicators Allocated to Research
Total number of people dedicated to clinical research in the institution
  • 40
    Researchers
  • 6
    Managers, Administrative, Legal and Financial
  • 2
    Study coordinators
  • 14
    Nurses
  • 10
    Pharmacists
Efficiency Indicators
  • 143
    Total number of participants recruited for clinical trials and interventional clinical studies of medical devices
  • 85%
    Patient recruitment rate in clinical trials and interventional clinical studies of medical devices
  • 30 days
    Average time to first patient recruitment in clinical trials and interventional clinical studies of medical devices
  • 15 days
    Average time between submission and approval of the Financial Contract in clinical trials and interventional clinical studies of medical devices

Clinical Research Areas of interest

Clinical Research Areas of interest

  • Breast, digestive, head and neck, lung, skin, urology, central nervous system, gynecology, hematology, endocrinology, and neuroendocrine cancers;
  • Oncogeriatrics;;
  • Oncosexology;
  • Palliative care;
  • Cancer Survivors;
  • Quality of life;
  • Nutrition, Rehabilitation and Exercise;
  • Non-pharmacological therapies;
  • Primary, secondary and tertiary prevention;
  • Epigenetics and Tumor Biology;
  • Molecular Oncology;
  • Phase II/III trials of new drugs or new therapies;
  • "Real Word Evidence" studies;
  • New techniques or technologies;
  • Radiobiology.

Gallery

Operating room

Operating room

Lab

Lab